Mobile

A worldwide placebo-controlled study to evaluate the additional lipid benefits of extended release (ER) niacin/laropiprant when taken with current lipid-modifying therapy in individuals with abnor...

Mise à jour : Il y a 4 ans
Référence : EUCTR2010-021627-27

A worldwide placebo-controlled study to evaluate the additional lipid benefits of extended release (ER) niacin/laropiprant when taken with current lipid-modifying therapy in individuals with abnormal lipids

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate the efficacy of ERN/LRPT 2 g relative to placebo on plasma LDL-C at Week 12 of treatment.

Critère d'inclusion

  • Primary Hypercholesterolemia or Mixed Dyslipidemia

Liens